{"key":"op_491_ES","page":{"url":"https://ru.bookimed.com/clinics/country=spain/procedure=kejtruda/","procedure":{"id":491,"slug":"kejtruda","name":"Иммунотерапия Кейтрудой (Пембролизумаб)","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"oncology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":34,"iso":"ES","name":"Испания"},"currency":"USD","data_date":{"status":"missing","reason":"not_collected"}},"pages":{"clinics_url":"https://ru.bookimed.com/clinics/country=spain/procedure=kejtruda/","cost_url":"https://ru.bookimed.com/clinics/country=spain/procedure=kejtruda/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":13600,"to":{"status":"missing","reason":"not_collected"},"avg":{"value":13558,"method":"median","source":"offers"},"us":{"from":13500,"to":22000},"uk":{"from":7000,"to":10500},"by_technique":{"status":"missing","reason":"not_collected"},"by_city":[{"city":"Барселона","from":13600},{"city":"Аликанте","from":5300},{"city":"Мадрид","from":6200}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"source":"offers","items":[{"tier":"basic","min":13558,"max":13558,"median":13558,"count":1}]},"comparison":[{"country_iso":"UA","from":4500,"to":8000},{"country_iso":"FR","from":4200,"to":7000},{"country_iso":"GB","from":7000,"to":10500},{"country_iso":"US","from":13500,"to":22000},{"country_iso":"IL","from":4800,"to":6800},{"country_iso":"TR","from":2800,"to":7000},{"country_iso":"MX","from":3800,"to":5500},{"country_iso":"DE","from":6000,"to":8100},{"country_iso":"CA","from":6800,"to":9800},{"country_iso":"AE","from":5600,"to":8600},{"country_iso":"TH","from":3600,"to":4600},{"country_iso":"PL","from":4300,"to":5800},{"country_iso":"KR","from":4800,"to":7500},{"country_iso":"CZ","from":3600,"to":5300},{"country_iso":"AT","from":5800,"to":8400},{"country_iso":"IT","from":4300,"to":6700},{"country_iso":"CN","from":4500,"to":7200},{"country_iso":"AU","from":4800,"to":7400},{"country_iso":"IN","from":2500,"to":5200},{"country_iso":"MY","from":3800,"to":5400},{"country_iso":"VN","from":4300,"to":6200},{"country_iso":"BR","from":4500,"to":7000},{"country_iso":"EG","from":1500,"to":6300}],"base_country":"US","base_is_fallback":false},"savings":{"pct":-1,"variant":"<15%"},"package":{"included":["Complete blood count with cancer markers and a proteinogram"],"excluded":["Accommodation is not included","Transfer is not included"],"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":5,"items":[{"id":6225,"name":"Hospital Ruber Internacional","city":"Madrid","rating":5,"reviews_count":3,"accreditations":["Joint Commission International","International Organization for Standardization"],"rank":1,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":78,"name":"Centro Médico Teknon","city":"Barcelona","rating":4.7,"reviews_count":497,"accreditations":["Joint Commission International","European Foundation for Quality Management","THE IMTJ MEDICAL TRAVEL AWARD WINNER IN 2019","Patient choice in Neurology","Patient choice in Neurosurgery","Patient choice for Epilepsy treatment","World's Best Hospitals 2021 by Newsweek"],"rank":2,"has_procedure":true,"why_ranked":"Offers immunotherapy with Keytruda, follows Memorial Sloan-Kettering protocols, and has a multidisciplinary team for personalized cancer treatment plans.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":[{"id":"63dbb2397e94b320d7053012","price":13558,"nights":0,"included":["Complete blood count with cancer markers and a proteinogram"],"excluded":["Accommodation is not included","Transfer is not included"],"other_services":"Treatment: Bladder cancer immunotherapy with Keytruda 200 mg injection Doctor: Dr. Joan Carles Galcerán Hospital level: Basic Recommended stay in the city: 1 night in the hotel Diagnostics: Not included in the package. Additional tests may be required depending on the patient’s previous oncology records, tumor stage, molecular profile and current general condition. Possible diagnostics if needed: Oncology consultation with Dr. Joan Carles Galcerán Review of medical reports and previous treatments Blood tests before immunotherapy Kidney and liver function tests Tumor markers, if clinically indicated CT scan / MRI / PET-CT for disease staging or follow-up Pathology review Molecular or immunohistochemical testing, if required Also includes: Keytruda / Pembrolizumab 200 mg Immunotherapy administration Day-hospital treatment supervision Medical team fees Nursing care during administration Medication preparation Consumable materials Basic post-treatment recommendations Implant: No implant applicable This package is designed for patients with bladder cancer who may be candidates for immunotherapy with Keytruda / Pembrolizumab 200 mg. The treatment is planned and supervised by Dr. Joan Carles Galcerán, medical oncologist, according to the patient’s diagnosis, previous treatments, tumor stage and medical condition. Keytruda is an immunotherapy medication that helps the immune system recognize and attack cancer cells. It may be considered in selected bladder cancer patients depending on clinical criteria, previous treatment history and biomarker results. The package includes one Keytruda 200 mg administration, medical supervision, nursing care, medication preparation, consumable materials and day-hospital treatment support. The final indication for immunotherapy must be confirmed by the oncologist after reviewing the patient’s medical records and current test results."}]},{"id":279,"name":"Hospital Quiron Barcelona","city":"Barcelona","rating":4.4,"reviews_count":6,"accreditations":["Joint Commission International"],"rank":3,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":422,"name":"Hospital HM Nou Delfos","city":"Barcelona","rating":4.6,"reviews_count":5,"accreditations":["European Foundation for Quality Management","Certification according to DIN EN ISO 9001 by TÜV NORD CERT"],"rank":4,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":953,"name":"GenesisCare Clinics","city":"Madrid","rating":{"status":"missing","reason":"not_collected"},"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":{"status":"missing","reason":"not_collected"},"rank":5,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":4,"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":98,"slug":"barselona","name":"Барселона","clinics_count":1,"price_from":13600,"profile":{"city_type":"Mediterranean coastal city in Spain","access":["Barcelona Airport (BCN), 15 km southwest of city center"],"sources":["https://en.wikipedia.org/wiki/Barcelona","https://en.wikipedia.org/wiki/Barcelona–El_Prat_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":441,"slug":"alicante","name":"Аликанте","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":5300,"profile":{"city_type":"Mediterranean port city in Spain","access":["Alicante Airport (ALC), 9 km from the city"],"sources":["https://en.wikipedia.org/wiki/Alicante","https://en.wikipedia.org/wiki/Alicante%E2%80%93Elche_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":346,"slug":"madrid","name":"Мадрид","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":6200,"profile":{"city_type":"Capital and largest city of Spain","access":["Madrid Barajas Airport (MAD), 13 km from Puerta del Sol"],"sources":["https://en.wikipedia.org/wiki/Madrid","https://en.wikipedia.org/wiki/Madrid–Barajas_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":1,"active_with_related":1,"hospital_nights_median":0,"days_in_country_median":{"status":"missing","reason":"fewer than 10 offers with hotel days"},"top_offers":[{"id":"63dbb2397e94b320d7053012","clinic_id":78,"clinic_listed":true,"price":13558,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Complete blood count with cancer markers and a proteinogram"],"excluded":["Accommodation is not included","Transfer is not included"],"other_services":"Treatment: Bladder cancer immunotherapy with Keytruda 200 mg injection Doctor: Dr. Joan Carles Galcerán Hospital level: Basic Recommended stay in the city: 1 night in the hotel Diagnostics: Not included in the package. Additional tests may be required depending on the patient’s previous oncology records, tumor stage, molecular profile and current general condition. Possible diagnostics if needed: Oncology consultation with Dr. Joan Carles Galcerán Review of medical reports and previous treatments Blood tests before immunotherapy Kidney and liver function tests Tumor markers, if clinically indicated CT scan / MRI / PET-CT for disease staging or follow-up Pathology review Molecular or immunohistochemical testing, if required Also includes: Keytruda / Pembrolizumab 200 mg Immunotherapy administration Day-hospital treatment supervision Medical team fees Nursing care during administration Medication preparation Consumable materials Basic post-treatment recommendations Implant: No implant applicable This package is designed for patients with bladder cancer who may be candidates for immunotherapy with Keytruda / Pembrolizumab 200 mg. The treatment is planned and supervised by Dr. Joan Carles Galcerán, medical oncologist, according to the patient’s diagnosis, previous treatments, tumor stage and medical condition. Keytruda is an immunotherapy medication that helps the immune system recognize and attack cancer cells. It may be considered in selected bladder cancer patients depending on clinical criteria, previous treatment history and biomarker results. The package includes one Keytruda 200 mg administration, medical supervision, nursing care, medication preparation, consumable materials and day-hospital treatment support. The final indication for immunotherapy must be confirmed by the oncologist after reviewing the patient’s medical records and current test results.","is_package":true}],"packages":[{"id":"63dbb2397e94b320d7053012","clinic_id":78,"clinic_listed":true,"price":13558,"nights":0,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Complete blood count with cancer markers and a proteinogram"],"excluded":["Accommodation is not included","Transfer is not included"],"other_services":"Treatment: Bladder cancer immunotherapy with Keytruda 200 mg injection Doctor: Dr. Joan Carles Galcerán Hospital level: Basic Recommended stay in the city: 1 night in the hotel Diagnostics: Not included in the package. Additional tests may be required depending on the patient’s previous oncology records, tumor stage, molecular profile and current general condition. Possible diagnostics if needed: Oncology consultation with Dr. Joan Carles Galcerán Review of medical reports and previous treatments Blood tests before immunotherapy Kidney and liver function tests Tumor markers, if clinically indicated CT scan / MRI / PET-CT for disease staging or follow-up Pathology review Molecular or immunohistochemical testing, if required Also includes: Keytruda / Pembrolizumab 200 mg Immunotherapy administration Day-hospital treatment supervision Medical team fees Nursing care during administration Medication preparation Consumable materials Basic post-treatment recommendations Implant: No implant applicable This package is designed for patients with bladder cancer who may be candidates for immunotherapy with Keytruda / Pembrolizumab 200 mg. The treatment is planned and supervised by Dr. Joan Carles Galcerán, medical oncologist, according to the patient’s diagnosis, previous treatments, tumor stage and medical condition. Keytruda is an immunotherapy medication that helps the immune system recognize and attack cancer cells. It may be considered in selected bladder cancer patients depending on clinical criteria, previous treatment history and biomarker results. The package includes one Keytruda 200 mg administration, medical supervision, nursing care, medication preparation, consumable materials and day-hospital treatment support. The final indication for immunotherapy must be confirmed by the oncologist after reviewing the patient’s medical records and current test results.","is_package":true}],"related_packages":{"status":"missing","reason":"not_collected"},"other_packages":{"status":"missing","reason":"not_classified"}},"medical":{"indications":["Advanced or metastatic melanoma; adjuvant melanoma after resection","Non-small cell lung cancer (alone or with chemotherapy)","Head and neck squamous cell carcinoma","Classical Hodgkin lymphoma (relapsed/refractory)","Urothelial carcinoma","MSI-high/dMMR solid tumors including colorectal cancer","Other approved cancers (cervical, endometrial, gastric, renal, breast)","Merkel cell carcinoma"],"contraindications":["Prior severe hypersensitivity to pembrolizumab or its components","Pregnancy (can harm the fetus)","Severe active autoimmune disease needing immunosuppression (relative)","Active uncontrolled infection (relative; treat first)","Prior solid organ transplant (relative; graft rejection risk)"],"operation_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Dose (200 mg every 3 weeks or 400 mg every 6 weeks) infused over 30 minutes, plus brief observation."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":1,"max":35,"unit":"visits","qualifier":"Infusions every 3 or 6 weeks for up to about 2 years (35 three-weekly cycles) or until progression."},"stages":[{"code":"infusion_cycles","label":"Repeated intravenous pembrolizumab infusions every 3 or 6 weeks","after":{"min":0,"max":730,"unit":"days","qualifier":"Spans the whole course from the first infusion."}}],"qualifier":"Number of cycles depends on cancer type, regimen, response and tolerance."},"hospital_nights":{"value":0,"source":"offers","parsed_details":{"min":0,"max":0,"unit":"nights","qualifier":"Per infusion; given as an outpatient infusion with no overnight stay."}},"treatment_conditions":["outpatient"],"rehabilitation_days":{"min":0,"max":2,"unit":"days","qualifier":"Outpatient infusion with no surgical recovery; usual activities resume within 0-2 days, depending on fatigue and side effects."},"fly_home_after_days":{"min":1,"max":2,"unit":"days","qualifier":"Outpatient infusion with no wound; flying is possible once no reaction occurs and you feel well."},"back_to_work_days":{"min":0,"max":2,"unit":"days","qualifier":"Most return to usual activities within 0-2 days, depending on fatigue, side effects and cancer type."},"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"No procedural restriction; light activity encouraged. Strenuous exercise within about a week, limited by fatigue."},"final_result_months":{"min":3,"max":6,"unit":"months","qualifier":"Best response often seen within 3-6 months; responses may deepen later."},"result_longevity":"In responders, benefit is often durable, lasting years and sometimes continuing after the course (up to about 2 years) ends. Duration depends on cancer type, stage and biomarkers.","main_risks":["Immune-related organ inflammation (lungs, colon, liver, thyroid, kidneys, skin)","Fatigue, rash, itching, diarrhea, nausea","Infusion-related reactions","Type 1 diabetes, adrenal or pituitary insufficiency","Myocarditis (rare)","Serious or fatal immune events needing steroids and interruption"],"complication_rate_pct":{"min":10,"max":20,"unit":"percent","qualifier":"Grade 3-5 treatment-related adverse events with monotherapy in pivotal trials; higher with chemotherapy or TKIs."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Overall survival at 5 years (advanced NSCLC, PD-L1 ≥50%)","value":31.9,"horizon":"5 years","source":{"status":"missing","reason":"not_collected"},"evidence_status":"limited"},"scars":"No scarring is expected; at most there is a tiny, temporary mark at the IV cannulation site.","pain":"Minimal; only mild discomfort from IV cannulation. Side effects such as joint or muscle pain may occur in some patients.","preparation":["Confirmed cancer and approved indication; biomarker testing if relevant","Baseline blood tests: liver, kidney, thyroid, glucose","Baseline imaging for staging","Review of autoimmune history, transplant history and current medications","Pregnancy test and contraception counseling where relevant","Discussion of side effects and when to report symptoms urgently","Hepatitis B/C and HIV screening; exclude active tuberculosis","Baseline ECOG performance status assessment","Adequate venous access for intravenous infusion"],"recovery_timeline":[{"phase":"Infusion day","description":"About 30-minute IV infusion with brief observation; most patients go home the same day.","restrictions":{"status":"missing","reason":"not_collected"}},{"phase":"First days after each infusion","description":"Possible mild fatigue, rash or flu-like symptoms. Promptly report cough, breathlessness, severe diarrhea or rash, jaundice or weakness.","restrictions":{"status":"missing","reason":"not_collected"}},{"phase":"Ongoing treatment","description":"Cycles every 3 or 6 weeks with monitoring for delayed immune-related side effects, which can appear months into treatment or after it ends.","restrictions":["Do not self-treat immune-related symptoms; contact the oncology team"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":21,"max":42,"unit":"days","qualifier":"Clinical review and blood tests before each subsequent cycle (every 3 or 6 weeks depending on regimen)."}},{"purpose":"result_review","requirement":"routine","after":{"min":42,"max":84,"unit":"days","qualifier":"First response imaging is typically about 6-12 weeks after starting treatment."}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that the medical team treating you has suitable qualifications","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you checked the qualifications of the medical team treating you?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Check that you can ask the treating team questions about your treatment","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you been able to ask them questions about your treatment?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C3","text":"Check that you are satisfied with the facilities and standards where you will be treated","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Are you satisfied with the facilities and standards at the clinic or hospital where you'll be treated?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C4","text":"Check how your aftercare will be coordinated once treatment is over","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Ensure you're clear about how your aftercare will be coordinated.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C5","text":"Check whether follow-up care takes place at the same facility as the procedure","scope":"treatment_abroad","source":{"url":"https://www.cdc.gov/yellow-book/hcp/health-care-abroad/medical-tourism.html","host":"cdc.gov","quote":"Medical tourists should also know whether follow-up care is scheduled to occur at the same facility as the procedure.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":403}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"The clinic or hospital refuses to discuss the details of the treatment when asked","scope":"treatment_abroad","source":{"url":"https://www.rcseng.ac.uk/patient-care/cosmetic-surgery/having-surgery-abroad","host":"rcseng.ac.uk","quote":"Be wary of surgeons and hospitals that do not want to discuss the details of surgery with you.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Fevers or flu-like symptoms with a rash","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Contact your care team right away if you notice fevers or flu-like symptoms with a rash.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Allergic reaction to the medicine","urgency":"contact_clinic","general":false,"source":{"url":"https://www.healthline.com/health/drugs/keytruda","host":"healthline.com","quote":"Call your doctor right away if you have an allergic reaction to Keytruda.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Any change in eyesight","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Tell your care team right away if you have any change in your eyesight.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Shortness of breath or trouble breathing","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Dry cough, shortness of breath or trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W5","text":"Chest pain or fast or irregular heartbeat","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Heart muscle inflammation—unusual weakness or fatigue, shortness of breath, chest pain, fast or irregular heartbeat.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Gives your home doctor information about your treatment and future care needs","document":"discharge letter for gp","source":{"url":"https://www.nhs.uk/using-the-nhs/nhs-services/hospitals/being-discharged-from-hospital/","host":"nhs.uk","quote":"You'll also be given a letter for your GP, providing information about your treatment and future care needs.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T4","text":"Tells any doctor the patient is on immunotherapy, so side effects are managed correctly","document":"immunotherapy wallet card","source":{"url":"https://www.ons.org/toolkits/immunotherapy-patient-wallet-card-1","host":"ons.org","quote":"The ONS Immunotherapy Patient Wallet Card is intended to communicate with healthcare providers who are not involved with a patient's cancer treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Blood tests","aliases":["Blood tests","Baseline blood tests","Recent blood tests"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"Liver function test","aliases":["Liver function test","liver","liver function","LFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"Kidney function test","aliases":["Kidney function test","kidney","kidney function","renal function"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"Thyroid function test","aliases":["Thyroid function test","thyroid","thyroid function","TFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Blood glucose test","aliases":["Blood glucose test","glucose","blood glucose"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Pregnancy test","aliases":["Pregnancy test"],"kind":"lab","origin":[{"field":"preparation","text":"Pregnancy test and contraception counseling where relevant"}],"what_it_checks":{"text":"Checks whether pregnancy is present because treatment can cause fetal harm","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Hepatitis B test","aliases":["Hepatitis B test","Hepatitis B/C screening","hepatitis B screening","HBV","Hepatitis C test","hepatitis C screening","HCV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"HIV test","aliases":["HIV test","HIV screening","HIV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"PD-L1 test","aliases":["PD-L1 test","PD-L1","PD-L1 test results"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Shows PD-L1 protein in tumor cells, guiding immunotherapy choice","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"A PD-L1 test uses a sample of cancerous tumor tissue to measure how much of a protein called programmed-death ligand 1 (PD-L1) is found on the cancer cells.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"type":"case","text":"If you have certain types of cancer","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"You may need a PD-L1 test if you've been diagnosed with certain types of cancer that commonly cause high PD-L1 levels.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"test_prep":{"text":"Preparation varies with how the tumor sample is collected","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"Preparations for your test depend on how your tissue sample will be taken.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}},{"id":"T10","name":"MSI test","aliases":["MSI test","MSI","microsatellite instability"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Checks tumor MSI-high status, which decides if Keytruda can treat it","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":2},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"visit_and_day":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":0,"max":2,"unit":"days","qualifier":"Most return to usual activities within 0-2 days, depending on fatigue, side effects and cancer type."},"complication_rate_pct":{"min":10,"max":20,"unit":"percent","qualifier":"Grade 3-5 treatment-related adverse events with monotherapy in pivotal trials; higher with chemotherapy or TKIs."},"contraindications":["Prior severe hypersensitivity to pembrolizumab or its components","Pregnancy (can harm the fetus)","Severe active autoimmune disease needing immunosuppression (relative)","Active uncontrolled infection (relative; treat first)","Prior solid organ transplant (relative; graft rejection risk)"],"days_in_clinic":{"min":0,"max":0,"unit":"nights","qualifier":"Per infusion; given as an outpatient infusion with no overnight stay."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"No procedural restriction; light activity encouraged. Strenuous exercise within about a week, limited by fatigue."},"final_result_months":{"min":3,"max":6,"unit":"months","qualifier":"Best response often seen within 3-6 months; responses may deepen later."},"fly_home_after_days":{"min":1,"max":2,"unit":"days","qualifier":"Outpatient infusion with no wound; flying is possible once no reaction occurs and you feel well."},"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":21,"max":42,"unit":"days","qualifier":"Clinical review and blood tests before each subsequent cycle (every 3 or 6 weeks depending on regimen)."}},{"purpose":"result_review","requirement":"routine","after":{"min":42,"max":84,"unit":"days","qualifier":"First response imaging is typically about 6-12 weeks after starting treatment."}}],"indications":["Advanced or metastatic melanoma; adjuvant melanoma after resection","Non-small cell lung cancer (alone or with chemotherapy)","Head and neck squamous cell carcinoma","Classical Hodgkin lymphoma (relapsed/refractory)","Urothelial carcinoma","MSI-high/dMMR solid tumors including colorectal cancer","Other approved cancers (cervical, endometrial, gastric, renal, breast)","Merkel cell carcinoma"],"main_risks":["Immune-related organ inflammation (lungs, colon, liver, thyroid, kidneys, skin)","Fatigue, rash, itching, diarrhea, nausea","Infusion-related reactions","Type 1 diabetes, adrenal or pituitary insufficiency","Myocarditis (rare)","Serious or fatal immune events needing steroids and interruption"],"pain":"Minimal; only mild discomfort from IV cannulation. Side effects such as joint or muscle pain may occur in some patients.","preparation":["Confirmed cancer and approved indication; biomarker testing if relevant","Baseline blood tests: liver, kidney, thyroid, glucose","Baseline imaging for staging","Review of autoimmune history, transplant history and current medications","Pregnancy test and contraception counseling where relevant","Discussion of side effects and when to report symptoms urgently","Hepatitis B/C and HIV screening; exclude active tuberculosis","Baseline ECOG performance status assessment","Adequate venous access for intravenous infusion"],"recovery_timeline":[{"phase":"Infusion day","description":"About 30-minute IV infusion with brief observation; most patients go home the same day.","restrictions":[]},{"phase":"First days after each infusion","description":"Possible mild fatigue, rash or flu-like symptoms. Promptly report cough, breathlessness, severe diarrhea or rash, jaundice or weakness.","restrictions":[]},{"phase":"Ongoing treatment","description":"Cycles every 3 or 6 weeks with monitoring for delayed immune-related side effects, which can appear months into treatment or after it ends.","restrictions":["Do not self-treat immune-related symptoms; contact the oncology team"]}],"rehabilitation_days":{"min":0,"max":2,"unit":"days","qualifier":"Outpatient infusion with no surgical recovery; usual activities resume within 0-2 days, depending on fatigue and side effects."},"result_longevity":"In responders, benefit is often durable, lasting years and sometimes continuing after the course (up to about 2 years) ends. Duration depends on cancer type, stage and biomarkers.","revision_rate_pct":null,"scars":"No scarring is expected; at most there is a tiny, temporary mark at the IV cannulation site.","sessions_or_stages":{"sessions":{"min":1,"max":35,"unit":"visits","qualifier":"Infusions every 3 or 6 weeks for up to about 2 years (35 three-weekly cycles) or until progression."},"stages":[{"code":"infusion_cycles","label":"Repeated intravenous pembrolizumab infusions every 3 or 6 weeks","after":{"min":0,"max":730,"unit":"days","qualifier":"Spans the whole course from the first infusion."}}],"qualifier":"Number of cycles depends on cancer type, regimen, response and tolerance."},"success":{"metric":"Overall survival at 5 years (advanced NSCLC, PD-L1 ≥50%)","value":31.9,"unit":"percent","horizon":"5 years","population":"Adults with untreated advanced NSCLC, PD-L1 ≥50%, on pembrolizumab monotherapy","evidence_status":"limited"},"techniques":[{"name":"Pembrolizumab monotherapy","suits_whom":"Patients with suitable biomarkers (e.g., high PD-L1, MSI-high) or melanoma","recovery":"Outpatient infusion; no downtime in most patients."},{"name":"Pembrolizumab combined with chemotherapy","suits_whom":"Patients such as those with non-small cell lung cancer or other tumors where the combination is approved","recovery":"Added chemotherapy side effects can increase fatigue and recovery time after each cycle."}],"treatment_conditions":["outpatient"],"treatment_duration_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Dose (200 mg every 3 weeks or 400 mg every 6 weeks) infused over 30 minutes, plus brief observation."},"initial_assessment_documents":["Pathology report with histology","PD-L1, MSI or dMMR test results","Staging CT or PET-CT reports","Prior treatment and surgery summary","Recent blood tests with liver and thyroid function","Oncologist letter on autoimmune disease or ECOG status"],"travel_trips":{"min":2,"max":35,"one_trip_possible":false,"qualifier":"Each 3- or 6-weekly infusion needs a visit; stay 1-3 days per trip. Fewer if a local oncologist continues."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that the medical team treating you has suitable qualifications","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you checked the qualifications of the medical team treating you?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Check that you can ask the treating team questions about your treatment","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you been able to ask them questions about your treatment?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C3","text":"Check that you are satisfied with the facilities and standards where you will be treated","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Are you satisfied with the facilities and standards at the clinic or hospital where you'll be treated?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C4","text":"Check how your aftercare will be coordinated once treatment is over","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Ensure you're clear about how your aftercare will be coordinated.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C5","text":"Check whether follow-up care takes place at the same facility as the procedure","scope":"treatment_abroad","source":{"url":"https://www.cdc.gov/yellow-book/hcp/health-care-abroad/medical-tourism.html","host":"cdc.gov","quote":"Medical tourists should also know whether follow-up care is scheduled to occur at the same facility as the procedure.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":403}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"The clinic or hospital refuses to discuss the details of the treatment when asked","scope":"treatment_abroad","source":{"url":"https://www.rcseng.ac.uk/patient-care/cosmetic-surgery/having-surgery-abroad","host":"rcseng.ac.uk","quote":"Be wary of surgeons and hospitals that do not want to discuss the details of surgery with you.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Fevers or flu-like symptoms with a rash","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Contact your care team right away if you notice fevers or flu-like symptoms with a rash.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Allergic reaction to the medicine","urgency":"contact_clinic","general":false,"source":{"url":"https://www.healthline.com/health/drugs/keytruda","host":"healthline.com","quote":"Call your doctor right away if you have an allergic reaction to Keytruda.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Any change in eyesight","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Tell your care team right away if you have any change in your eyesight.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Shortness of breath or trouble breathing","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Dry cough, shortness of breath or trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W5","text":"Chest pain or fast or irregular heartbeat","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Heart muscle inflammation—unusual weakness or fatigue, shortness of breath, chest pain, fast or irregular heartbeat.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Gives your home doctor information about your treatment and future care needs","document":"discharge letter for gp","source":{"url":"https://www.nhs.uk/using-the-nhs/nhs-services/hospitals/being-discharged-from-hospital/","host":"nhs.uk","quote":"You'll also be given a letter for your GP, providing information about your treatment and future care needs.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T4","text":"Tells any doctor the patient is on immunotherapy, so side effects are managed correctly","document":"immunotherapy wallet card","source":{"url":"https://www.ons.org/toolkits/immunotherapy-patient-wallet-card-1","host":"ons.org","quote":"The ONS Immunotherapy Patient Wallet Card is intended to communicate with healthcare providers who are not involved with a patient's cancer treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"Your advanced lung cancer has spread to other body parts","name":"Targeted medicines for lung cancer","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment","host":"nhs.uk","quote":"Targeted medicines or immunotherapy are sometimes used to treat advanced lung cancer that has spread to other parts of the body.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"technique_details":{"status":"ok","items":[{"id":"pembrolizumab-monotherapy","name":"Pembrolizumab monotherapy","how_it_works":{"text":"The antibody blocks immune-inhibiting signals, allowing an anti-tumor immune response","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=pembro","host":"nctr-crs.fda.gov","quote":"Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"pembrolizumab-combined","name":"Pembrolizumab combined with chemotherapy","how_it_works":{"text":"The antibody is administered with another cancer treatment to treat cancer","source":{"url":"https://api.fda.gov/drug/label.json?search=openfda.application_number:%22BLA761467%22&limit=1","host":"api.fda.gov","quote":"The most common adverse reactions (≥20%) in patients receiving intravenous pembrolizumab and axitinib were diarrhea, fatigue/asthenia, hypertension, hypothyroidism, decreased appetite, hepatotoxicity, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Blood tests","aliases":["Blood tests","Baseline blood tests","Recent blood tests"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"Liver function test","aliases":["Liver function test","liver","liver function","LFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"Kidney function test","aliases":["Kidney function test","kidney","kidney function","renal function"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"Thyroid function test","aliases":["Thyroid function test","thyroid","thyroid function","TFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Blood glucose test","aliases":["Blood glucose test","glucose","blood glucose"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Pregnancy test","aliases":["Pregnancy test"],"kind":"lab","origin":[{"field":"preparation","text":"Pregnancy test and contraception counseling where relevant"}],"what_it_checks":{"text":"Checks whether pregnancy is present because treatment can cause fetal harm","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Hepatitis B test","aliases":["Hepatitis B test","Hepatitis B/C screening","hepatitis B screening","HBV","Hepatitis C test","hepatitis C screening","HCV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"HIV test","aliases":["HIV test","HIV screening","HIV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"PD-L1 test","aliases":["PD-L1 test","PD-L1","PD-L1 test results"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Shows PD-L1 protein in tumor cells, guiding immunotherapy choice","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"A PD-L1 test uses a sample of cancerous tumor tissue to measure how much of a protein called programmed-death ligand 1 (PD-L1) is found on the cancer cells.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"type":"case","text":"If you have certain types of cancer","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"You may need a PD-L1 test if you've been diagnosed with certain types of cancer that commonly cause high PD-L1 levels.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"test_prep":{"text":"Preparation varies with how the tumor sample is collected","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"Preparations for your test depend on how your tissue sample will be taken.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}},{"id":"T10","name":"MSI test","aliases":["MSI test","MSI","microsatellite instability"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Checks tumor MSI-high status, which decides if Keytruda can treat it","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":2},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"visit_and_day":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"}}},"techniques":[{"id":"pembrolizumab-monotherapy","name":"Pembrolizumab monotherapy","how_it_works":{"id":"H1","text":"The antibody blocks immune-inhibiting signals, allowing an anti-tumor immune response","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=pembro","host":"nctr-crs.fda.gov","quote":"Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Patients with suitable biomarkers (e.g., high PD-L1, MSI-high) or melanoma","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Outpatient infusion; no downtime in most patients."},{"id":"pembrolizumab-combined","name":"Pembrolizumab combined with chemotherapy","how_it_works":{"id":"H1","text":"The antibody is administered with another cancer treatment to treat cancer","source":{"url":"https://api.fda.gov/drug/label.json?search=openfda.application_number:%22BLA761467%22&limit=1","host":"api.fda.gov","quote":"The most common adverse reactions (≥20%) in patients receiving intravenous pembrolizumab and axitinib were diarrhea, fatigue/asthenia, hypertension, hypothyroidism, decreased appetite, hepatotoxicity, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Patients such as those with non-small cell lung cancer or other tumors where the combination is approved","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Added chemotherapy side effects can increase fatigue and recovery time after each cycle."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"Your advanced lung cancer has spread to other body parts","name":"Targeted medicines for lung cancer","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment","host":"nhs.uk","quote":"Targeted medicines or immunotherapy are sometimes used to treat advanced lung cancer that has spread to other parts of the body.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-11","next_check_at":"2027-02-09"},"travel":{"status":"ok","items":[{"id":"V1","item":"passport_validity","audience":"uk","volatile":true,"text":"The passport must have an expiry date at least 3 months after you plan to leave the Schengen area","source":{"url":"https://www.gov.uk/foreign-travel-advice/spain/entry-requirements","host":"gov.uk","quote":"have an ‘expiry date’ at least 3 months after the day you plan to leave the Schengen area (the expiry date does not need to be within 10 years of the date of issue)","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"medicines","audience":"all","volatile":false,"text":"Carry prescription medication in its original packaging, along with your doctor's prescription","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Spain.html","host":"travel.state.gov","quote":"Always carry your prescription medication in original packaging, along with your doctor’s prescription.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"prescriptions","audience":"us","volatile":false,"text":"Medications that require a prescription in the United States also require a local doctor's prescription in Spain","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Spain.html","host":"travel.state.gov","quote":"Medications requiring prescriptions in the United States also require a local doctor’s prescription in Spain.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V4","item":"ghic","audience":"uk","volatile":false,"text":"A GHIC or EHIC is needed to get medically necessary state healthcare in Spain","source":{"url":"https://www.gov.uk/foreign-travel-advice/spain/health","host":"gov.uk","quote":"To get medically necessary state healthcare in Spain, you need a Global Health Insurance Card ( GHIC ) or a European Health Insurance Card ( EHIC ).","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V5","item":"hospital_payment","audience":"all","volatile":false,"text":"Private hospitals usually require payment or proof of insurance or funds before admitting a patient","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Spain.html","host":"travel.state.gov","quote":"Private hospitals usually require payment or proof insurance or funds before admitting a patient.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V6","item":"emergency_number","audience":"all","volatile":false,"text":"Dial 112 and ask for an ambulance","source":{"url":"https://www.gov.uk/foreign-travel-advice/spain/health","host":"gov.uk","quote":"Dial 112 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["azerbaijan","china","dominican-republic","egypt","germany","india","israel","italy","japan","malaysia","mexico","morocco","republic-of-korea","switzerland","thailand","turkey","ukraine","united-states"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.7,"count":511,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>The cost of immunotherapy with Keytruda (pembrolizumab) in Spain generally runs <strong>from _price_from_ to _price_to_</strong>. Pricing depends on factors such as the number of treatment cycles, the patient’s diagnosis, and the hospital’s location. In the United States, the average cost is <strong>_price_compare_us_average_</strong> (per NCCN guidelines). This means immunotherapy with Keytruda in Spain is typically about _price_percent_discount_% less than in the U.S.</p><p>Spanish hospitals usually include the drug itself, oncologist consultations, infusion sessions, and routine monitoring in the price. In the U.S., medication, administration, and follow-up visits are often billed separately. Always confirm what’s included with each clinic or hospital before starting treatment.</p>","faq":[{"q":"What is Keytruda (Pembrolizumab)?","a":"<p>Keytruda is an immune checkpoint inhibitor designed to help the immune system detect and destroy cancer cells. This PD-1 inhibitor immunotherapy blocks proteins that prevent T-cells from attacking tumors. It is widely used in Spain for melanoma, lung cancer, and triple-negative breast cancer.</p> <ul> <li><strong>Method of action:</strong> Intravenous infusion targeting PD-1 receptors to reactivate immune responses against various malignant cells.</li> <li><strong>Clinical combinations:</strong> Frequently paired with chemotherapy drugs like cisplatin or Lenvatinib to enhance metastatic survival.</li> <li><strong>Patient monitoring:</strong> Requires tracking liver enzyme levels and thyroid function to prevent potential autoimmune-like reactions.</li> <li><strong>Spanish expertise:</strong> Available at Joint Commission International-accredited centers like Centro Médico Teknon and Hospital Quiron.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Spanish oncology centers like Centro Médico Teknon manage high volumes, performing 23,500 operations annually. Patients often choose Spain because top specialists like Dr. Francesc Bosch manage over 80 clinical trials simultaneously. This provides access to advanced drug combinations before they become standard elsewhere.</p> <p><strong>Patient Consensus:</strong> Many survivors report vanishing metastases within 9 months, though managing early side effects like fatigue or diarrhea is vital. Some describe the feeling as inducing a temporary autoimmune condition while the immune system reactivates.</p>"},{"q":"How is Keytruda administered?","a":"<p>Keytruda is primarily administered through intravenous infusion or a newer subcutaneous injection. Most patients receive the medication via an IV line in an outpatient clinical setting. The procedure usually takes 30 to 60 minutes and occurs every 3 or 6 weeks depending on the specific cancer diagnosis.</p> <ul> <li><strong>Intravenous method:</strong> Surgeons use a butterfly needle for painless delivery directly into the vein.</li> <li><strong>Infusion duration:</strong> Each session typically lasts 30 to 60 minutes in an outpatient clinic.</li> <li><strong>Subcutaneous injection:</strong> Keytruda Qlex offers a faster alternative taking roughly 1 to 2 minutes.</li> <li><strong>Treatment frequency:</strong> Regimens occur every 3 or 6 weeks depending on PD-L1 expression levels.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While many patients focus on the 30-minute infusion time, top Spanish centers like Centro Médico Teknon integrate comprehensive blood monitoring into the same visit. Our data shows that high-profile patients choose these JCI-accredited facilities because they bundle cancer markers and proteinograms directly with the Keytruda administration to ensure immediate safety tracking.</p> <p><strong>Patient Consensus:</strong> Infusions are generally painless, and many patients continue working remotely without taking full sick leave. It is vital to maintain isolation precautions during the regimen because the treatment can make you immunocompromised.</p>"},{"q":"What should I track during Keytruda treatment?","a":"<p>During Keytruda treatment, you must track immune-related adverse events affecting the lungs, liver, and endocrine system. Monitor for new coughs, shortness of breath, skin rashes, or extreme fatigue. In Spain, JCI-accredited clinics like Centro Médico Teknon require regular laboratory monitoring of liver enzymes and thyroid function.</p> <ul> <li><strong>Respiratory health:</strong> Report any new cough or chest pain immediately to rule out pneumonitis.</li> <li><strong>Organ function:</strong> Track liver enzymes and TSH levels through scheduled blood work in Barcelona clinics.</li> <li><strong>Gastrointestinal changes:</strong> Log diarrhea frequency or stomach pain to monitor for potential immune-mediated colitis.</li> <li><strong>Energy levels:</strong> Record daily fatigue scores as exhaustion is the most frequent side effect reported.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While many focus on major organ failure, data shows minor thyroid shifts often signal early immune responses. Patients at top Spanish centers like Hospital Quiron Barcelona often see hair thinning or joint pain before TSH levels drop. Tracking these subtle changes can help your oncologist adjust treatments before severe symptoms develop.</p> <p><strong>Patient Consensus:</strong> Patients emphasize the need for a daily symptom diary to distinguish between normal tiredness and treatment-induced exhaustion. Many recommend early imaging scans if respiratory issues emerge, rather than waiting for the next scheduled infusion.</p>"}],"h2":[{"text":"Как это работает","kind":"content"},{"text":"Какая цена иммунотерапии кейтрудой (пембролизумаб) в Испании?","kind":"content"},{"text":"Предложения по иммунотерапии Кейтрудой (Пембролизумаб) в Испании — ноябрь 2026","kind":"content"},{"text":"Лучшие клиники по иммунотерапии Кейтрудой (Пембролизумаб) в Испании — 5 проверенных вариантов с ценами","kind":"content"},{"text":"Обзор процедуры Иммунотерапия Кейтрудой (Пембролизумаб) в Испании","kind":"content"},{"text":"Получите медицинскую консультацию по иммунотерапии Кейтрудой (Пембролизумаб) в Испании: Выбирайте среди лучших специалистов в этой области","kind":"content"},{"text":"Видеоистории пациентов Bookimed","kind":"content"},{"text":"Отзывы о Bookimed: узнайте о реальном опыте пациентов","kind":"content"},{"text":"Поделитесь этим материалом","kind":"content"},{"text":"Ключевые факты о иммунотерапии Кейтрудой (Пембролизумаб)","kind":"content"},{"text":"FAQ по иммунотерапии Кейтрудой (Пембролизумаб) в Испании","kind":"content"},{"text":"Получить бесплатную консультацию","kind":"content"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}